Trial Profile
Quadrivalent Human Papillomavirus (qHPV) Vaccine in Cancer Survivors: Cross Sectional Survey and Phase II Open-Label Vaccine Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; V 503 (Primary)
- Indications Cervical cancer; Human papillomavirus infections; Penile cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 07 Oct 2021 Status changed from active, no longer recruiting to completed.
- 24 Sep 2020 Planned End Date changed from 1 Aug 2020 to 1 Dec 2021.
- 16 Jul 2019 Planned End Date changed from 1 Nov 2020 to 1 Aug 2020.